The trial demonstrated that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters and reached its anticipated endpoints.
IFX-1 was designed to control the inflammatory response in acute diseases, lead by the sepsis indication.
InflaRx co-founder and CEO said Niels Riedemann said they completed successful clinical Phase I trial with IFX-1 within their first financing round and in less than four years development.
"Our strategic positioning in Jena, with our strong clinical ties to the sepsis, puts us in a unique position to tackle the challenges of clinical development of IFX-1," Riedemann added.